TB-500

Featured

Also known as: Thymosin Beta-4, TB4

A synthetic fragment of thymosin beta-4 that promotes tissue repair, cell migration, and angiogenesis.

Overview

TB-500 is a synthetic version of thymosin beta-4, a 43-amino acid peptide found in all tissues except red blood cells. It plays critical roles in tissue repair, cell migration, and blood vessel formation.

Mechanism of Action

TB-500 sequesters G-actin and promotes F-actin formation, essential for cell motility. Upregulates actin and enhances cell migration to injury sites. Promotes angiogenesis and reduces inflammation.

Pharmacokinetics

Distributed systemically with preferential accumulation at injury sites. Half-life approximately 2 hours but effects persist longer.

Dosing Protocols

Note: These are research protocols from literature. This is not medical advice.

1

Loading

Dose

2-2.5 mg

Frequency

Twice weekly

Duration

4-6 weeks

Initial loading phase

2

Maintenance

Dose

2 mg

Frequency

Once weekly

Duration

4-8 weeks

Maintenance phase

Stacking Recommendations

Peptides that may be combined based on complementary mechanisms in research settings.

Rationale: Comprehensive healing

Synergy: Different phases of wound healing addressed

Rationale: Tissue remodeling

Synergy: Enhanced collagen synthesis and repair

Research Areas

Wound HealingCardiac RepairMuscle RecoveryHair GrowthNeuroprotection

Key Research Findings

  • 1Promoted cardiac repair in mouse myocardial infarction models
  • 2Enhanced wound healing and reduced scar formation
  • 3Demonstrated hair growth stimulation in preclinical studies
  • 4Neuroprotective effects in stroke models

Side Effects & Contraindications

Reported Side Effects

  • Injection site reactions
  • Headache (rare)
  • Lethargy (rare)

Contraindications

  • Active cancer
  • Pregnancy

Safety Considerations

Generally well-tolerated. Theoretical concerns about tumor promotion, though not demonstrated.

Storage Requirements

Store lyophilized at -20C. Reconstituted stable at 2-8C for 14 days.

Scientific References

Quick Reference

Sequence
LKKTETQ (active region)
Molecular Weight
4963 g/mol (full Tb4)
Half-Life
~2 hours
Bioavailability
High (SC, IM)
Research Stage
clinical phase 2
Administration
Subcutaneous or intramuscular injection